CO2019010860A2 - Una formulación líquida de anticuerpo contra tnf alfa - Google Patents

Una formulación líquida de anticuerpo contra tnf alfa

Info

Publication number
CO2019010860A2
CO2019010860A2 CONC2019/0010860A CO2019010860A CO2019010860A2 CO 2019010860 A2 CO2019010860 A2 CO 2019010860A2 CO 2019010860 A CO2019010860 A CO 2019010860A CO 2019010860 A2 CO2019010860 A2 CO 2019010860A2
Authority
CO
Colombia
Prior art keywords
liquid formulation
antibody against
tnf alpha
against tnf
alpha
Prior art date
Application number
CONC2019/0010860A
Other languages
English (en)
Inventor
Sora Yun
Youn Kyung Ko
Jin Eon So
Original Assignee
Lg Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63522490&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2019010860(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd
Publication of CO2019010860A2 publication Critical patent/CO2019010860A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a una formulación líquida de un anticuerpo contra TNF-α, específicamente a una formulación líquida de adalimumab.
CONC2019/0010860A 2017-03-16 2019-09-30 Una formulación líquida de anticuerpo contra tnf alfa CO2019010860A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20170033188 2017-03-16
PCT/KR2018/003097 WO2018169348A1 (ko) 2017-03-16 2018-03-16 항-tnf 알파 항체의 액상 제제

Publications (1)

Publication Number Publication Date
CO2019010860A2 true CO2019010860A2 (es) 2020-01-17

Family

ID=63522490

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0010860A CO2019010860A2 (es) 2017-03-16 2019-09-30 Una formulación líquida de anticuerpo contra tnf alfa

Country Status (15)

Country Link
JP (2) JP7109849B2 (es)
KR (2) KR20180106974A (es)
CN (1) CN110621303A (es)
AU (1) AU2018236651B2 (es)
BR (1) BR112019019162A2 (es)
CO (1) CO2019010860A2 (es)
MA (1) MA46988A1 (es)
MX (1) MX2019010895A (es)
MY (1) MY197202A (es)
NZ (1) NZ757965A (es)
PH (1) PH12019502075A1 (es)
RU (1) RU2756619C2 (es)
UA (1) UA123847C2 (es)
WO (1) WO2018169348A1 (es)
ZA (1) ZA201906696B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021015034A2 (pt) 2019-02-18 2021-10-05 Eli Lilly And Company Formulação de anticorpo terapêutico
TW202102260A (zh) * 2019-03-21 2021-01-16 美商再生元醫藥公司 含有抗ｉｌ－３３抗體之穩定調配物
US20230173068A1 (en) * 2020-02-20 2023-06-08 Bio-Thera Solutions, Ltd. ANTI-TNF-a ANTIBODY FORMULATION, PREPARATION METHOD THEREFOR AND USE THEREOF

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140186361A1 (en) * 2012-09-07 2014-07-03 Coherus Biosciences, Inc. Stable Aqueous Formulations of Adalimumab
CN103458926B (zh) * 2010-11-11 2016-10-26 艾伯维生物技术有限公司 改进的高浓度抗TNF α 抗体液体制剂
UY34105A (es) * 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
SG10201609982PA (en) * 2012-03-07 2017-01-27 Cadila Healthcare Ltd Pharmaceutical formulations of tnf-alpha anitbodies
EP2948473A1 (en) * 2013-01-24 2015-12-02 GlaxoSmithKline Intellectual Property Development Limited Tnf-alpha antigen-binding proteins
AR095496A1 (es) * 2013-03-15 2015-10-21 Bayer Healthcare Llc Formulaciones de anticuerpos anti-receptor de prolactina
US20150274819A1 (en) * 2014-03-03 2015-10-01 La Jolla Biologics, Inc. Stable aqueous recombinant protein formulations
WO2015151115A1 (en) * 2014-04-02 2015-10-08 Intas Pharmaceuticals Limited Liquid pharmaceutical composition of adalimumab
EP3050557A1 (en) * 2014-05-23 2016-08-03 Ares Trading S.A. Liquid pharmaceutical composition
US9821059B2 (en) * 2014-10-17 2017-11-21 Alteogen Inc. Composition for stabilizing protein and pharmaceutical formulation comprising the same
HUP1400510A1 (hu) * 2014-10-28 2016-05-30 Richter Gedeon Nyrt Gyógyászati TNFalfa ellenes antitest készítmény
US20180016333A1 (en) * 2015-01-28 2018-01-18 Mabxience, S.A. Pharmaceutical formulations for anti-tnf-alpha antibodies
WO2016162819A1 (en) * 2015-04-07 2016-10-13 Lupin Limited Stable aqueous pharmaceutical composition of anti-tnf alpha antibody

Also Published As

Publication number Publication date
JP2020510079A (ja) 2020-04-02
MY197202A (en) 2023-05-31
JP2022097600A (ja) 2022-06-30
RU2019130728A3 (es) 2021-04-16
KR20200096472A (ko) 2020-08-12
JP7109849B2 (ja) 2022-08-01
WO2018169348A1 (ko) 2018-09-20
AU2018236651A1 (en) 2019-10-31
UA123847C2 (uk) 2021-06-09
KR20180106974A (ko) 2018-10-01
PH12019502075A1 (en) 2020-09-14
MA46988A1 (fr) 2020-06-30
RU2756619C2 (ru) 2021-10-04
AU2018236651B2 (en) 2020-12-10
NZ757965A (en) 2022-07-01
MX2019010895A (es) 2019-11-05
KR102342292B1 (ko) 2021-12-24
ZA201906696B (en) 2020-08-26
BR112019019162A2 (pt) 2020-04-14
RU2019130728A (ru) 2021-04-16
CN110621303A (zh) 2019-12-27

Similar Documents

Publication Publication Date Title
ECSP18007905A (es) Anticuerpos monoclonales contra bcma
CL2018001488A1 (es) Formulación farmacéutica acuosa del anticuerpo anti-pd-l1 avelumab
EP4257613A3 (en) Bispecific checkpoint inhibitor antibodies
MD3370770T2 (ro) Formulări subcutanate de anticorpi anti-CD38 și utilizări ale acestora
CL2016002455A1 (es) Anticuerpos multiespecíficos.
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
MY198059A (en) Anti-ox40 antibodies and their uses
EP4335874A3 (en) Anti-hla-g antibodies and use thereof
BR112017008666A2 (pt) anticorpos anti-fgfr2/3 e métodos de uso dos mesmos
BR112018074468A2 (pt) anticorpos anti-cd40 e suas utilizações
EA201691610A1 (ru) Анти-jagged1 антитела и способы применения
CO2019010860A2 (es) Una formulación líquida de anticuerpo contra tnf alfa
BR112017015880A2 (pt) anticorpos, usos e métodos
CL2017002055A1 (es) Muestra de líquido
EA201992027A1 (ru) Водный состав антитела против pd-l1
BR112018002382A8 (pt) Novos anticorpos anti-gvpi humano e usos dos mesmos
TWD192262S (zh) Infusion Pump
UY36107A (es) Composición microencapsulada inhibidora de la nitrificación
BR112016027455A2 (pt) moduladores ppar
CL2017001957U1 (es) Almohadilla urinaria masculina.
EP3738091A4 (en) USE OF SOCIAL ENGAGEMENT TO GENERATE METAGAMING RESOURCES
EA201792266A1 (ru) Способ получения соединения на основе ртути, соединение на основе ртути, способы применения соединения на основе ртути и применения соединения на основе ртути
MA39411A (fr) Synthèse de l'énantiomère de la progestérone et ses intermédiaires
CL2017003414S1 (es) Hervidor solar
CL2019000555S1 (es) Licuadora.